NCT Number: NCT04428788 Phase: Phase 1 Trial Summary: The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate canc – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Celgene Acronym:
Clinical Trials
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
June 23rd, 2023 | Clinical TrialsBiomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
June 23rd, 2023 | Clinical TrialsNCT Number: NCT04349501 Phase: Phase 2 Trial Summary: Adult male patients with high-risk, localized prostate cancer and planning to undergo radiation therapy (RT) with androgen deprivation therapy (ADT) will undergo an advanced Magnet – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of California, San Diego Acronym: ProsRSI
The Impact of Low Pressure Pneumo in RARP II
June 23rd, 2023 | Clinical TrialsNCT Number: NCT04394676 Phase: Not Applicable Trial Summary: The purpose of this study is to evaluate clinical significance of low pressure pneumoperitoneum during robotically assisted radical prostatectomy (RAR – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Metro Health, Michigan Acronym:
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
June 23rd, 2023 | Clinical TrialsNCT Number: NCT04388852 Phase: Phase 1 Trial Summary: This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI) […]
Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients
June 23rd, 2023 | Clinical TrialsNCT Number: NCT04353973 Phase: NA Trial Summary: This study aims to determine if web-based eHealth delivery of pre-test and/or post-test counseling in cancer patients and/or those at risk for cancer can provide equal or improved – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Abramson Cancer Center at Penn Medicine Acronym: eReach
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
June 23rd, 2023 | Clinical TrialsNCT Number: NCT04373564 Phase: PHASE4 Trial Summary: This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detaile – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Guerbet Acronym: ODYSSEY
AMNIOX CORD Study – Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
June 23rd, 2023 | Clinical TrialsNCT Number: NCT04263025 Phase: PHASE2|PHASE3 Trial Summary: This study aims at evaluating if placement of CLARIX® CORD 1K during robotic prostatectomy decreases the time to achieve complete erectile and urinary function after the surgery. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Hackensack Meridian Health Acronym:
Radium-223 in Biochemically Recurrent Prostate Cancer
June 23rd, 2023 | Clinical TrialsNCT Number: NCT04206319 Phase: Phase 2 Trial Summary: Some men who have been treated for localized prostate cancer with surgery or radiation still show signs of the disease in their blood. This is called biochemically recurrent prosta – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical […]
Serial MRI Scans During Radiation Therapy
June 23rd, 2023 | Clinical TrialsNCT Number: NCT04188535 Phase: Not Applicable Trial Summary: This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (s – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Dana-Farber Cancer Institute Acronym: RELAY
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
June 23rd, 2023 | Clinical TrialsNCT Number: NCT04253483 Phase: Phase 2 Trial Summary: This phase II trial compares high-dose rate brachytherapy and stereotactic ablative radiotherapy as monotherapy in treating patients with prostate cancer that has not spread to oth – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Rutgers, The State University of New Jersey|National Cancer Institute (NCI) Acronym: